Exicure
Biotechnology company that developed Spherical Nucleic Acid (SNA) technology for gene regulation, though the company has faced significant challenges and restructured operations.
Notes
Exicure was a biotechnology company that developed a proprietary Spherical Nucleic Acid (SNA) technology platform for gene regulation therapeutics. SNAs are nanostructures consisting of nucleic acids arranged in a spherical configuration, designed to enable efficient cellular uptake and gene modulation.
The company was originally based in Chicago and was publicly traded on NASDAQ (XCUR). However, Exicure faced significant business challenges, including clinical setbacks and financial difficulties, leading to restructuring efforts.
Note: Investors should verify the current operating status of Exicure, as the company has undergone significant changes.
Team
- Historical leadership team - verify current status
Additional Research Findings
- Founded in 2012
- Portfolio company of Abingworth (historically)
- Headquarters: Chicago, Illinois
- Spherical Nucleic Acid (SNA) technology
- Former NASDAQ listing: XCUR
- Company faced restructuring challenges
- Verify current operating status
Sources
- Abingworth Portfolio
- Company status requires verification
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |